Entrada Therapeutics, Inc. (TRDA) Stock Price & Analysis
Entrada Therapeutics, Inc. (TRDA) rose 1.76% to USD 6.37 as of June 10, 2026 at 07:32 UTC, according to Nexqual real-time market data.
TRDA last closed at USD 6.26; the session ranged USD 6.15–6.69 on volume of 167,057 shares. Market capitalization is $247.29M, with a 52-week range of USD 4.93–16.45 (NGM). Source: Nexqual, June 10, 2026 at 07:32 UTC.
Key Statistics (as of June 10, 2026 at 07:32 UTC)
| Price | USD 6.37 |
|---|---|
| Change | ▲ 1.76% (up) |
| Previous Close | USD 6.26 |
| Open | USD 6.39 |
| Day Range | USD 6.15 – 6.69 |
| 52-Week Range | USD 4.93 – 16.45 |
| Volume | 167,057 shares |
| Market Cap | $247.29M |
| Exchange | NGM |
Technical Analysis (TRDA)
Nexqual's technical model rates TRDA "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 07:32 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 34.34 (neutral) |
| vs SMA50 | Below (USD 10.54) |
| MACD | -1.13 (negative) |
Analyst Ratings (TRDA)
Wall Street analysts rate TRDA "Strong Buy" based on 4 analysts, with a mean price target of USD 18.75 (range USD 10–25), per Nexqual as of June 10, 2026 at 07:32 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 18.75 |
| High Target | USD 25 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 7 / 1 / 0 |
Earnings (TRDA)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -1.04 |
| Revenue Estimate | $2.23M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.95 vs est -1.02 ▲ beat |
| 2025-12-31 | USD -0.94 vs est -1.16 ▲ beat |
| 2025-09-30 | USD -1.06 vs est -0.97 ▼ miss |
| 2025-06-30 | USD -1.04 vs est -0.86 ▼ miss |
Source: Nexqual, June 10, 2026 at 07:32 UTC.
Financials & Fundamentals (TRDA)
| Total Revenue | $5.74M |
|---|---|
| Revenue Growth (YoY) | -95.70% |
| Gross Margin | +0.00% |
| Operating Margin | -4834.63% |
| Profit Margin | +0.00% |
| ROE | -48.28% |
| Debt / Equity | 18.37 |
| Current Ratio | 13.9 |
| Total Cash | $254.86M |
| Total Debt | $49.75M |
| Free Cash Flow | $-75.38M |
Source: Nexqual, June 10, 2026 at 07:32 UTC.
Financial Health Score (TRDA)
Nexqual rates Entrada Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 07:32 UTC.
| Growth | Critical — Revenue -88% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $255M cash vs $50M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$75M, burning cash |
| Efficiency | Critical — ROE -48%, ROA -26.8% |
Ownership (TRDA)
| Insider Ownership | +12.31% |
|---|---|
| Institutional Ownership | +78.38% |
| Shares Outstanding | 38.82M |
| Float | 19.50M |
| Short % of Float | +6.91% |
Source: Nexqual, June 10, 2026 at 07:32 UTC.
Leadership (TRDA)
Entrada Therapeutics, Inc. is led by Dipal Doshi (age 49), CEO & Director, per Nexqual as of June 10, 2026 at 07:32 UTC.
| CEO & Director | Dipal Doshi (age 49) |
|---|---|
| President & COO | Nathan J. Dowden (age 54) |
| President of Research & Development | Natarajan Sethuraman (age 63) |
| CFO & Treasurer | Kory James Wentworth (age 46) |
| Senior Vice President of People | Kerry Robert M.S. |
Major Backers & Investors (TRDA)
Notable institutional backers of Entrada Therapeutics, Inc. include Baker Bros. Advisors, LP, 5AM Venture Management, LLC, TCG Crossover Management, LLC, according to Nexqual as of June 10, 2026 at 07:32 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Baker Bros. Advisors, LP | 13.07% |
| 5AM Venture Management, LLC | 10.45% |
| TCG Crossover Management, LLC | 5.89% |
| Merck & Co., Inc. | 4.48% |
| Wellington Management | 2.67% |
| StepStone Group LP | 1.96% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.87% |
| Vanguard Group | 6.76% |
| Geode Capital | 1.72% |
| State Street | 1.38% |
Source: Nexqual, June 10, 2026 at 07:32 UTC.
From Entrada Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- The cornerstone of our platform, our proprietary EEV peptides are based upon small cyclic peptides of approximately 10 amino acid residues or fewer.
- Intellectual Property We strive to protect our proprietary technology, inventions, improvements, platforms, program candidates, therapeutic candidates and components thereof, their methods of use and processes for their manufacture that we believe are important to our business, including by obtaining, maintaining, defending and enforcing patent and other intellectual property rights for the foregoing in the U.S. and in foreign jurisdictions.
- The portfolio includes patents covering certain embodiments of the EEV Platform that don't relate to our lead therapeutic candidates with granted patents in the U.S. (3), India, Japan, China, Hong Kong and Europe (including 37 European validation states).
- At the same time, however, as in our neuromuscular franchise, initial targets are selected based on well-understood biology, significant unmet need, translational clarity and the potential to differentiate based on our proprietary technologies and capabilities.
Partnerships
- In addition, our VX-670 partnership with Vertex Pharmaceuticals Incorporated ("Vertex") continues to progress, with dosing completion anticipated in mid-2026.
- Complementing the ongoing clinical progress of the DMD franchise is the myotonic dystrophy type 1 ("DM1") partnership with Vertex ("VX-670").
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TYRA | Tyra Biosciences, Inc. | USD 25.94 | ▼ 2.63% |
| JBIO | Jade Biosciences, Inc. | USD 15.22 | ▼ 10.15% |
| AURA | Aura Biosciences, Inc. | USD 6.35 | ▼ 4.22% |
| DSGN | Design Therapeutics, Inc. | USD 10.55 | ▼ 0.94% |
| EWTX | Edgewise Therapeutics, Inc. | USD 34.06 | ▼ 4.3% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:32 UTC. This page is informational and not investment advice.